AXGN · AXOGEN INC Q2 FY2026 earnings call record财报电话会记录

“As reported this morning in our earnings release, second quarter revenue was $69.7 million, up 23.1% versus the second quarter of 2025, reflecting broad-based growth across all three target markets.”

“Breast led the way, contributing approximately 2/3 of the quarter's growth, with first half 2026 revenue up 47% year-over-year.”

“Gross margin for the quarter was 72.7%, compared to 74.2% for the second quarter of 2025 and less than our plan.”

“We will address these changes in product mix through pricing actions and production efficiency initiatives.”

“As we look ahead, our decision to move forward will be guided by the market opportunity, the ability to standardize and scale the Avance technique, surgeon feedback on clinical impact, and evidence of patient demand that can help shape the care pathway.”

“Gross margin decreased 150 basis points year-over-year, driven by 4.6% higher product costs, partially offset by 2.7% lower write-offs.”

“Gross margin in the second quarter was less than our internal projections, primarily due to, one, selling more higher-cost biologic Avance starting in April than expected, and two, the demand for certain long-length Avance growing faster than the rest of the Avance portfolio.”

“These two factors impacted gross margin approximately 1% versus our internal expectations.”

“We have consistently outperformed our long-range revenue growth target of 15%-20% CAGR and believe we remain well positioned to continue doing so.”

“Sales and marketing expenses as a percentage of total revenue increased 2.2 percentage points to 44.2% in the second quarter, compared to 42% in the second quarter of 2025.”

“We now expect full year 2026 revenue growth of at least 24%, or revenue of at least $279 million.”

“The initial data set that we will present on has been done within the constraint of robotic surgical interventions.”